首页> 外文期刊>Canadian pharmacists journal: CPJ = Revue des pharmaciens du Canada : RPC >A randomized controlled trial of a community pharmacist-initiated screening and intervention program for patients at high risk for osteoporosis - the OsteoPharm study
【24h】

A randomized controlled trial of a community pharmacist-initiated screening and intervention program for patients at high risk for osteoporosis - the OsteoPharm study

机译:社区药剂师启动的筛查和干预计划针对骨质疏松症高风险患者的随机对照试验-OsteoPharm研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To determine the effect of a community pharmacist-initiated screening intervention for high-risk patients on subsequent testing and treatment of osteoporosis. Methods: This was a randomized, controlled multisite trial with blinded ascertainment of outcomes in 15 community pharmacies in Alberta. Patients were recruited based on national guidelines for bone mineral density (BMD) testing, including patients 65 years or older, or between 50 to 64 years with a previous fracture or with multiple other risk factors. We excluded patients who had a BMD in the past 2 years or if they were on current treatment for osteoporosis. Patients randomized to the intervention group were given education, a quantitative heel ultrasound measurement and referred to their physician. Controls received "usual care" in the community. The primary outcome was a composite endpoint of the performance of a BMD test or a new prescription for an osteoporosis medication within 4 months. Secondary outcomes included each component of the primary outcome, calcium and vitamin D supplementation, osteoporosis-related knowledge and quality of life.Results: From November 2005 to September 2007, 561 patients were screened. Overall, 262 were randomized as follows: 129 pharmacist interventions and 133 controls. Median age was 62 years, 65% were female and 17% of patients reported a previous fracture. The primary end-point was reached in 28 patients in the intervention group (22%) compared with 14 patients in the control group (11%) (adjusted relative increase 2.14, 95% CI 1.19-3.85; p = 0.011). Calcium intake increased significantly more among intervention patients than controls (42% vs 25%, adjusted relative increase 1.69, 95% CI 1.13-2.54, p = 0.011); vitamin D intake was also greater in the intervention group, though not significant. There was no effect on knowledge or quality of life. In multivariable models, making an osteoporosis-specific appointment with the family physician, being female and having a heel ultrasound result indicating low bone mass predicted achievement of the primary endpoint.Conclusion: A multifaceted intervention program in community pharmacies directed at patients at high risk for osteoporosis doubled the number of patients getting the primary outcome. This study highlights the role community pharmacists can play in identifying and educating patients for preventive care.
机译:目的:确定社区药剂师发起的筛查干预措施对高危患者的骨质疏松症后续检测和治疗的效果。方法:这是一项在阿尔伯塔省15家社区药房进行盲法确定结果的随机对照多站点试验。根据国家骨矿物质密度(BMD)测试指南招募患者,包括65岁或65岁以上,或50至64岁之间有先前骨折或多种其他危险因素的患者。我们排除了过去2年内患有BMD或目前正在接受骨质疏松症治疗的患者。随机分配至干预组的患者接受了教育,定量足跟超声测量,并转介给了他们的医生。控件在社区中获得了“常规护理”。主要结局是在4个月内进行BMD测试或新处方骨质疏松症药物的综合终点。次要结局包括主要结局的各个组成部分,补充钙和维生素D,与骨质疏松症相关的知识以及生活质量。结果:从2005年11月至2007年9月,筛查了561例患者。总体而言,将262例患者随机分组如下:129例药剂师干预和133例对照。中位年龄为62岁,其中65%为女性,17%的患者曾报告过骨折。干预组中28例患者(22%)达到了主要终点,而对照组中14例患者(11%)达到了主要终点(校正后相对增加2.14,95%CI 1.19-3.85; p = 0.011)。干预组患者的钙摄入量显着高于对照组(42%比25%,调整后的相对增加1.69,95%CI 1.13-2.54,p = 0.011);干预组的维生素D摄入量也较高,尽管并不显着。对知识或生活质量没有影响。在多变量模型中,与女性的家庭医生预约骨质疏松症,女性且足跟超声检查结果表明骨量低预测了主要终点的完成。结论:针对高风险患者的社区药房的多方面干预计划骨质疏松症使获得主要结果的患者人数增加了一倍。这项研究强调了社区药剂师在识别和教育患者进行预防保健方面可以发挥的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号